127 related articles for article (PubMed ID: 35382723)
1. Potential Neuroprotective Effect of Cannabinoids in COVID-19 Patients.
Cortes-Altamirano JL; Yáñez-Pizaña A; Reyes-Long S; Angélica GM; Bandala C; Bonilla-Jaime H; Alfaro-Rodríguez A
Curr Top Med Chem; 2022; 22(16):1326-1345. PubMed ID: 35382723
[TBL] [Abstract][Full Text] [Related]
2. Anti-Inflammatory and Antiviral Effects of Cannabinoids in Inhibiting and Preventing SARS-CoV-2 Infection.
Janecki M; Graczyk M; Lewandowska AA; Pawlak Ł
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456990
[TBL] [Abstract][Full Text] [Related]
3. HDAC Inhibition as Neuroprotection in COVID-19 Infection.
Sixto-López Y; Correa-Basurto J
Curr Top Med Chem; 2022; 22(16):1369-1378. PubMed ID: 35240959
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoids Receptors in COVID-19: Perpetrators and Victims.
Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Batiha GE
Curr Med Chem; 2023; 30(34):3832-3845. PubMed ID: 36043749
[TBL] [Abstract][Full Text] [Related]
5. Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19?
Costa LHA; Santos BM; Branco LGS
Eur J Pharmacol; 2020 Dec; 889():173629. PubMed ID: 33022271
[TBL] [Abstract][Full Text] [Related]
6. Neurological disorders of COVID-19: insights to applications of natural products from plants and microorganisms.
Almasi F; Dang W; Mohammadipanah F; Li N
Arch Pharm Res; 2022 Dec; 45(12):909-937. PubMed ID: 36441470
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective Agents with Therapeutic Potential for COVID-19.
Zaa CA; Espitia C; Reyes-Barrera KL; An Z; Velasco-Velázquez MA
Biomolecules; 2023 Oct; 13(11):. PubMed ID: 38002267
[TBL] [Abstract][Full Text] [Related]
8. In quest of a new therapeutic approach in COVID-19: the endocannabinoid system.
Lucaciu O; Aghiorghiesei O; Petrescu NB; Mirica IC; Benea HRC; Apostu D
Drug Metab Rev; 2021 Nov; 53(4):478-490. PubMed ID: 33683968
[TBL] [Abstract][Full Text] [Related]
9. Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients.
Yachou Y; El Idrissi A; Belapasov V; Ait Benali S
Neurol Sci; 2020 Oct; 41(10):2657-2669. PubMed ID: 32725449
[TBL] [Abstract][Full Text] [Related]
10. Implications of Cannabis and Cannabinoid Use in COVID-19: Scoping Review.
Pereira CF; Vargas D; Toneloto FL; Ito VD; Volpato RJ
Rev Bras Enferm; 2022; 75Suppl 1(Suppl 1):e20201374. PubMed ID: 35262598
[TBL] [Abstract][Full Text] [Related]
11. CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2 infections.
Nagoor Meeran MF; Sharma C; Goyal SN; Kumar S; Ojha S
Drug Dev Res; 2021 Feb; 82(1):7-11. PubMed ID: 33190277
[TBL] [Abstract][Full Text] [Related]
12. Potential Immunotherapeutic Targets for Hypoxia Due to COVI-Flu.
Leyfman Y; Erick TK; Reddy SS; Galwankar S; Nanayakkara PWB; Di Somma S; Sharma P; Stawicki SP; Chaudry IH
Shock; 2020 Oct; 54(4):438-450. PubMed ID: 32649367
[TBL] [Abstract][Full Text] [Related]
13. Neuro-COVID-19: an insidious virus in action.
Bratosiewicz-Wąsik J
Neurol Neurochir Pol; 2022; 56(1):48-60. PubMed ID: 34642927
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer's, Parkinson's, and Huntington's Diseases.
Pérez-Olives C; Rivas-Santisteban R; Lillo J; Navarro G; Franco R
Adv Exp Med Biol; 2021; 1264():81-92. PubMed ID: 33332005
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 and neurologic manifestations: a synthesis from the child neurologist's corner.
Valderas C; Méndez G; Echeverría A; Suarez N; Julio K; Sandoval F
World J Pediatr; 2022 Jun; 18(6):373-382. PubMed ID: 35476245
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoids and neuroprotection in motor-related disorders.
de Lago E; Fernández-Ruiz J
CNS Neurol Disord Drug Targets; 2007 Dec; 6(6):377-87. PubMed ID: 18220777
[TBL] [Abstract][Full Text] [Related]
17. Severe Acute Respiratory Syndrome Coronavirus 2 Impact on the Central Nervous System: Are Astrocytes and Microglia Main Players or Merely Bystanders?
Murta V; Villarreal A; Ramos AJ
ASN Neuro; 2020; 12():1759091420954960. PubMed ID: 32878468
[TBL] [Abstract][Full Text] [Related]
18. Putative mechanism of neurological damage in COVID-19 infection.
Bandala C; Cortes-Altamirano JL; Reyes-Long S; Lara-Padilla E; Ilizaliturri-Flores I; Alfaro-Rodríguez A
Acta Neurobiol Exp (Wars); 2021; 81(1):69-79. PubMed ID: 33949163
[TBL] [Abstract][Full Text] [Related]
19. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
[TBL] [Abstract][Full Text] [Related]
20. Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic.
Dewanjee S; Vallamkondu J; Kalra RS; Puvvada N; Kandimalla R; Reddy PH
Mol Neurobiol; 2021 Sep; 58(9):4694-4715. PubMed ID: 34169443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
